Equities

Kaken Pharmaceutical Co Ltd

Kaken Pharmaceutical Co Ltd

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (JPY)3,901.00
  • Today's Change-14.00 / -0.36%
  • Shares traded84.90k
  • 1 Year change+7.88%
  • Beta0.4722
Data delayed at least 20 minutes, as of Sep 19 2024 07:00 BST.
More ▼
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

KAKEN PHARMACEUTICAL CO., LTD. is a Japan-based company engaged in the production and sale of pharmaceutical products. The Company operates in two business segments. The Pharmaceutical segment involves in the manufacture and sale of pharmaceuticals, medical devices and agricultural drugs. The Real Estate segment is engaged in the leasing of real estate.

  • Revenue in JPY (TTM)72.15bn
  • Net income in JPY7.27bn
  • Incorporated1948
  • Employees1.14k
  • Location
    Kaken Pharmaceutical Co Ltd20F, Bunkyo Green Court Center Office2-28-8, HonkomagomeBUNKYO-KU 113-8650JapanJPN
  • Phone+81 359775001
  • Fax+81 359775131
  • Websitehttps://www.kaken.co.jp/
More ▼

Mergers & acquisitions

Acquired companyDeal statusDateDate /
Deal status
4521:TYO since
announced
Transaction
value
Eisai Co Ltd-Merislon & MyonalAnnounced29 Mar 202429 Mar 2024Announced14.20%25.10m
Data delayed at least 20 minutes, as of Sep 19 2024 07:00 BST.

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Kyorin Pharmaceutical Co Ltd120.10bn5.53bn97.62bn2.04k15.700.66759.860.812996.2496.242,091.352,263.710.68151.312.8358,813,420.003.143.054.073.7942.9047.114.604.761.30--0.137267.745.531.0212.68-4.987.41-7.06
Torii Pharmaceutical Co Ltd57.25bn5.25bn108.00bn583.0020.060.875318.981.89186.93186.932,036.864,284.470.43042.792.2398,195,540.003.956.524.367.3544.4949.559.1817.985.70--0.0024.1711.74-2.674.4428.76-20.3820.11
Nxera Pharma Co Ltd23.34bn-9.84bn116.78bn350.00--1.69--5.00-115.16-115.16270.92767.280.1792--5.0566,685,720.00-7.55-0.6588-8.18-0.703672.7189.83-42.14-4.463.96-8.450.5075---18.00---1,982.98------
Zeria Pharmaceutical Co Ltd78.88bn9.03bn118.83bn1.78k10.921.207.081.51204.82204.821,789.401,858.720.54181.503.7144,387,400.006.203.899.826.2873.2271.9311.447.570.8393--0.350835.0910.744.1424.7817.4920.775.29
Mochida Pharmaceutical Co Ltd103.55bn4.41bn121.03bn1.52k26.060.898816.621.17123.93123.932,908.723,593.560.65651.753.4268,032,190.002.804.373.345.3150.0552.474.266.713.31--0.0045.16-0.3641-1.26-31.61-11.6310.91-1.21
Towa Pharmaceutical Co Ltd235.95bn16.92bn152.38bn4.59k8.610.89334.320.6458343.72343.724,793.823,311.490.55821.493.6051,428,070.004.004.214.915.6335.9039.237.177.231.62--0.566621.019.1316.74634.803.7228.2010.86
Kissei Pharmaceutical Co Ltd77.43bn12.00bn172.10bn1.78k13.000.701910.482.22268.51268.511,728.184,972.530.32041.552.9043,524,450.005.003.615.383.9049.9049.4715.5912.694.93--0.00634.8711.980.89196.0015.286.5810.40
KAKEN PHARMACEUTICAL CO., LTD.72.15bn7.27bn179.85bn1.14k20.381.0417.922.49192.09192.091,906.843,763.430.4221.983.2363,566,520.004.256.834.887.8753.4154.7810.0814.483.98--0.026351.25-1.29-5.2147.52-14.700.36390.00
Sumitomo Pharma Co Ltd329.55bn-260.17bn229.59bn4.98k--1.43--0.6967-654.85-654.85829.49404.890.3281.203.8866,174,100.00-25.89-5.07-45.34-7.7360.2269.99-78.94-12.280.419--0.7079---43.38-7.29-322.71--4.02--
Nippon Shinyaku Co., Ltd.150.37bn27.37bn235.41bn2.21k8.250.99367.221.57406.30406.302,232.623,372.500.59761.373.2067,949,390.0010.8810.4512.4112.3166.8161.2718.2016.473.73--0.011432.622.835.2613.329.6645.9312.12
Sawai Group Holdings Co Ltd178.04bn17.78bn266.44bn3.48k15.011.258.821.50404.94584.994,058.784,883.080.46711.172.8351,130,670.003.480.71044.620.970531.1435.087.441.471.5843.190.292788.138.04-0.824946.82-2.3318.150.00
Data as of Sep 19 2024. Currency figures normalised to Kaken Pharmaceutical Co Ltd's reporting currency: Japanese Yen JPY

Institutional shareholders

15.65%Per cent of shares held by top holders
HolderShares% Held
Silchester International Investors LLPas of 26 Mar 20242.22m4.82%
The Vanguard Group, Inc.as of 04 Sep 20241.16m2.52%
Nomura Asset Management Co., Ltd.as of 30 Aug 20241.07m2.34%
Nikko Asset Management Co., Ltd.as of 06 Sep 2024499.40k1.09%
Daiwa Asset Management Co. Ltd.as of 30 Aug 2024480.30k1.05%
BlackRock Fund Advisorsas of 05 Sep 2024393.20k0.86%
Brandes Investment Partners LPas of 11 Sep 2024391.40k0.85%
Norges Bank Investment Managementas of 31 Dec 2023387.71k0.84%
Dimensional Fund Advisors LPas of 31 Jul 2024321.03k0.70%
Asset Management One Co., Ltd.as of 05 Sep 2024268.60k0.59%
More ▼
Data from 30 Jun 2024 - 30 Jun 2024Source: FactSet Research Systems Inc.
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.